‫شركة CHiQ تحوز على الجوائز الدولية لقوة علامتها التجارية

تشونغشان، الصين، 12 يناير 2023 /بي آر نيوزواير/ — تم مؤخرًا تصنيف تشانغهونغ، أكبر شركة مصنعة للأجهزة الكهربائية المنزلية الصينية وعلامتها التجارية المتميزة تشيك ( CHiQ) ، كواحدة من أفضل 10 علامات تجارية عالمية للتلفزيونات في عام 2022-2023. تعد أفضل العلامات التجارية العالمية حدثًا عالميًا يعبر عن الثقة والاحترافية والمصداقية – قاعة الشرف في مجال الإلكترونيات الاستهلاكية الدولية. تم الإعلان عن قائمة أفضل العلامات التجارية العالمية لعام 2022-2023 وعدد من جوائز المنتجات الفردية في المعرض الدولي السادس والخمسين للإلكترونيات الاستهلاكية ( CES 2023) ، وهو أحد أكبر عشر أحداث سنوية لصناعة التكنولوجيا العالمية، والذي أقيم في لاس فيغاس من 5 إلى 8 يناير. يمثل معرض الإلكترونيات الاستهلاكية لهذا العام بداية انتعاش واسع النطاق في حالة عدم الاتصال بالإنترنت.

أنشأت تشانغهونغ العلامة التجارية CHiQ للنمو طويل الأجل في مجال الأجهزة الإلكترونية الاستهلاكية التي تستخدم الإنترنت المنزلي. تقدم العلامة التجارية مجموعة متنوعة من المنتجات، بما في ذلك أجهزة التلفزيون والثلاجات ومكيفات الهواء. تتوقع تشانغهونغ أن تزود المستهلكين بتجربة معيشية أكثر راحة وقائمة على الاكتفاء الذاتي من خلال CHiQ .

وتجدر الإشارة إلى أن CHiQ قد توسعت بشكل مطرد في الأسواق العالمية منذ عام 2017، مع وجودها في أكثر من 30 دولة وأكثر من 40 منصة تجارة إلكترونية متعددة الأسواق بما في ذلك Amazon و Lazada و Shopee . ومن ثم فقد أصبحت CHiQ معروفة بشكل متزايد للمستهلكين خارج الصين بفضل قوتها والعديد من القنوات الإعلامية التي يتم من خلالها الترويج للعلامة التجارية والتي تعمل جميعها على زيادة تأثير العلامة التجارية، وهذا مع حصولها على جائزة ضمن أفضل 10 علامات تجارية عالمية للتلفزيونات في عام 2022-2023 والذي يعد بمثابة شهادة على نجاحها.

تهدف CHiQ إلى جعل منزل كل شخص مكان معيشة يمكن فيه تحقيق الرضا الروحي من خلال توفير مجموعة من المنتجات الذكية متميزة التصميم والمبتكرة التي تتوافق مع قيم حياته (من خلال كونها ملونة وجذابة وإيجابية وممتعة). وتحقيقًا لهذه الغاية، طورت CHiQ فكرة +المزيد (“حقق +المزيد في حياتك”)، والتي يمكن من خلالها تحقيق مفاهيم: تصميم أفضل، ومرح أكثر، وإبداع أكثر، واختيارات أكثر، ونمط أفضل، وقيمة أكبر.

واليوم تتوسع فئات منتجات CHiQ إلى ما وراء أجهزة التلفزيون والثلاجات ومكيفات الهواء لتشمل الغسالات والشاشات ومنظفات الأرضيات. كما تنمو القدرة التنافسية لخط إنتاجها في نفس الوقت. وتمثل المنتجات عالية الجودة أساس العلامة التجارية. وبوضع ذلك في الاعتبار، ستواصل CHiQ صقل قدراتها التقنية لتقديم منتجات ذكية وموثوقة توفر حياة ذكية رقميًا لمستخدميها.

صورة –  https://mma.prnewswire.com/media/1981274/image_5010092_23237735.jpg

Hisense Enriches Home Entertainment Options for South African Consumers with Launch of New U80H Mini-LED ULED 8K TV

CAPE TOWN, South Africa, Jan. 12, 2023 /PRNewswire/ — Leading global electronics brand, Hisense, has recently announced the launch of the U80H Mini-LED ULED 8K TV in South Africa. The U80H TV delivers never-before-seen depth and detail, with 33 million pixels – 4 times more than a standard 4K TV. The next-generation smart TV also comes with a number of innovative features, combing to create a truly immersive entertainment experience.

The U80H TV comes with an 8K AI Upscaler capable of upscaling picture performance to achieve exceptionally high-quality picture standards with accurate details. Instead of simply duplicating pixels, the smart algorithm can analyse images and render suitable pixels to enhance image quality and accuracy. In addition, the Hisense Hi-View Engine Pro integrates a set of deep learning algorithms to intelligently analyse images frame-by-frame and adjust pixels accurately, optimizing for shadows and brightness. Together, these innovative tools achieve high dynamic range, high colour gamut, high definition, and high motion fluency display.

The U80H TV utilizes the Hisense Mini-LED Pro which optimizes for more than 500 local dimming zones to bring noticeable improvements in brightness range, visibility of details, and sharpness between bright and dark images. With Quantum Dot Colour, the three primary colours are displayed far more accurately than conventional LED TVs, and cutting-edge HDR10+ leverages dynamic metadata from each frame to adjust for colour, brightness, and contrast parameters, making for a much more realistic-looking image. For sound, although able to be connected to any speaker device, the U80H TV also features world-class Dolby Atmos® technology to provide an ultra-rich listening experience.

The U80H TV has built-in Android TV, meaning users can choose from 400,000+ movies and shows from across streaming services. The product sells itself as ‘the only way to experience IMAX-like signature picture, sound, and scale in your home,’ with IMAX® Enhanced which combines digitally remastered 4K HDR content and DTS® audio technologies with best-in-class consumer electronics products and streaming platforms. In terms of entertainment modes, the devices support Game Mode PRO with eARC, ALLM, and VRR to minimise input lag, screen jitter and shaking.

For easy use, these modes and other functions are accessible through hands-free voice control, allowing users to only use their voice to search, tune into, and control TV and smart home devices.

The Hisense 75 inch U80H is available from Hirsch’s. Please check https://hisense.co.za/products/hisense-u80h-mini-led-uled-8k-tv/.

Photo – https://mma.prnewswire.com/media/1982077/image_5020023_14499256.jpg

Zenas BioPharma administra a primeira dose em paciente, dando início à Fase 3 do Estudo Clínico do Obexelimab para o tratamento de doença relacionada à imunoglobulina G4 (IgG4-RD)

O estudo Global de Fase 3 INDIGO avaliará a eficácia e a segurança do obexelimab em pacientes com IgG4-RD, uma doença fibroinflamatória crônica e grave que normalmente afeta múltiplos órgãos

A IgG4-RD é a primeira de várias indicações potenciais de doença a serem testadas com o obexelimab, dada sua inibição única de células B não depletoras

WALTHAM, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias imunológicas, anunciou hoje que administrou a primeira dose em paciente na Fase 3 do estudo INDIGO de registro do obexelimab. O estudo INDIGO avaliará a eficácia clínica e a segurança do tratamento com obexelimab na prevenção do surto de doença relacionada à IgG4 (IgG4-RD). O obexelimab é um anticorpo bifuncional de alta afinidade que inibe as linhagens de células B ao se ligar simultaneamente a CD19 e Fc RIIB, regulando negativamente a atividade das células B em pacientes com doenças autoimunes associadas a autoanticorpos, como IgG4-RD.

“A IgG4-RD é uma condição fibroinflamatória crônica e grave que pode afetar quase qualquer sistema de órgãos e pode ter um impacto profundo em muitos pacientes, levando a danos graves nos órgãos ou até a morte”, disse Hua Mu, MD, Ph.D., Diretor Executivo da Zenas. “Atualmente não há nenhum tratamento aprovado para pacientes com IgG4-RD. Com base nos dados promissores de um estudo de Fase 2 do obexelimab em pacientes com IgG4-RD, estamos bem otimistas ao dar continuidade à avaliação do potencial do obexelimab no estudo INDIGO.”

Sobre o Estudo INDIGO

O estudo INDIGO é um estudo global multicêntrico, randomizado, duplo-cego, controlado por placebo, envolvendo até 200 adultos com sinais/sintomas ativos de IgG4-RD (ou seja, exacerbação) que requerem terapia com esteroides. Os pacientes serão randomizados em uma proporção de 1:1 para receber obexelimab ou placebo, administrados com injeções subcutâneas.

O objetivo primário do INDIGO é o tempo para o primeiro surto de IgG4-RD (definido como o reaparecimento de sinais/sintomas anteriores ou o aparecimento de novos sinais/sintomas de IgG4-RD) que requeira o início da terapia de resgate desde a randomização até à Semana 52. A segurança será avaliada durante todo o estudo.

Mais informações sobre o estudo INDIGO (NCT05662241) estão disponíveis em clinicaltrials.gov.

Sobre o Obexelimab

O obexelimab é um novo anticorpo bifuncional de Fase 3 em investigação com potencial de primeira classe que inibe as linhagens de células B que expressam CD19. A ligação simultânea ao CD19 e FcƳRIIB do obexelimab imita um complexo antígeno-anticorpo natural e sobrerregula a atividade das células B. Em vários estudos clínicos em fase inicial, 198 indivíduos foram tratados com obexelimab. Nestes estudos clínicos, a molécula demonstrou a inibição eficaz da função das células B sem a redução das células, e um efeito encorajador no tratamento de doentes com múltiplas doenças autoimunes. Zenas adquire da Xencor, Inc. direitos mundiais exclusivos do obexelimab.

Sobre a IgG4-RD

A IgG4-RD é uma doença fibroinflamatória crônica e grave que afeta tipicamente múltiplos órgãos (por exemplo, pâncreas, fígado, rim, ducto biliar, glândulas salivares e lacrimais). Aproximadamente 20.000 pessoas são diagnosticadas com IgG4-RD nos EUA, com taxas de prevalência semelhantes em todas as áreas geográficas. Muitos pacientes têm algum grau de dano irreversível a um órgão no momento do diagnóstico. Embora quase todos os pacientes respondam inicialmente à terapia com glicocorticoides (GC), a maioria dos pacientes apresenta recaída/surto dentro de alguns meses após a descontinuação do tratamento, exigindo terapia de resgate. A terapia de GC crônica também está associada à toxicidade em muitos pacientes.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial comprometida em se tornar líder global no desenvolvimento e comercialização de terapias imunológicas para pacientes em todo o mundo. Com desenvolvimento clínico e operações globais, a Zenas está avançando um portfólio global profundo e equilibrado das melhores terapêuticas autoimunes em potencial em áreas de alta necessidade médicas, atendendo aos requisitos de valor do dinâmico ambiente global de saúde. O pipeline da empresa continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas com doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Joe Farmer, Presidente e COO
Zenas BioPharma
IR@zenasbio.com

GlobeNewswire Distribution ID 8728679

Zenas BioPharma annonce qu’un premier patient a reçu une dose dans le cadre d’une étude clinique de phase 3 sur l’obéxélimab pour le traitement de la maladie liée aux immunoglobulines G4 (ML-IgG4)

La phase 3 de l’étude mondiale INDIGO évaluera l’efficacité et l’innocuité de l’obéxélimab chez des patients atteints de la ML-IgG4, une maladie fibro-inflammatoire chronique et grave qui affecte généralement plusieurs organes

La ML-IgG4 est la première de plusieurs indications de maladies potentielles à faire l’objet de recherche pour l’obéxélimab compte tenu de son inhibition unique des lymphocytes B non déplétive

WALTHAM, Massachussetts, 12 janv. 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, société biopharmaceutique mondiale déterminée à devenir leader dans le développement et la commercialisation de traitements immunitaires, a annoncé aujourd’hui que le premier patient avait reçu une dose dans le cadre de la phase 3 de l’étude d’enregistrement INDIGO sur l’obéxélimab. L’étude INDIGO doit évaluer l’efficacité et l’innocuité clinique du traitement par obéxélimab dans la prévention des poussées de la maladie liée aux IgG4 (ML-IgG4). L’obéxélimab est un anticorps bifonctionnel de haute affinité qui inhibe les lignées de cellules B en se liant simultanément au CD19 et au FcƳRIIB, régulant ainsi à la baisse l’activité des lymphocytes B chez les patients atteints de maladies auto-immunes associées à des auto-anticorps, comme la ML-IgG4.

« La ML-IgG4 est un trouble fibro-inflammatoire chronique et grave qui peut affecter presque tous les systèmes d’organes et peut avoir un impact profond sur de nombreux patients, entraînant de graves lésions des organes ou le décès », a déclaré Hua Mu, M.D., titulaire d’un doctorat, président-directeur général de Zenas. « Il n’existe actuellement aucun traitement approuvé pour les patients vivant avec la ML-IgG4. Sur la base des données prometteuses fournies par l’étude de phase 2 sur l’obéxélimab menée chez des patients atteints de la ML-IgG4, nous sommes ravis de continuer à évaluer le potentiel de l’obéxélimab dans l’étude INDIGO. »

À propos de l’étude INDIGO

L’étude INDIGO est une étude multicentrique, randomisée, en double aveugle et contrôlée par placebo recrutant jusqu’à 200 adultes qui présentent des signes/symptômes actifs de la ML-IgG4 (c-à-d. une poussée) et qui nécessitent une corticothérapie. Les patients seront randomisés selon un ratio de 1:1 pour recevoir soit de l’obéxélimab, soit un placebo, administré par injections sous-cutanées.

Le critère d’évaluation principal d’INDIGO est le délai avant la première poussée de la ML-IgG4 (définie comme la réapparition de signes/symptômes antérieurs ou l’apparition de nouveaux signes/symptômes de la ML-IgG4) qui nécessite le début d’un traitement de secours de la randomisation à la semaine 52. L’innocuité sera évaluée tout au long de l’étude.

Plus d’informations sur l’étude INDIGO (NCT05662241) sont disponibles sur clinicaltrials.gov.

À propos de l’obéxélimab

L’obéxélimab est un nouvel anticorps bifonctionnel expérimental de phase 3 avec un potentiel de première classe qui inhibe les lignées de cellules B exprimant la protéine CD19. La liaison simultanée avec la protéine CD19 et le recombinant FcƳRIIB par l’obéxélimab imite un complexe antigène-anticorps naturel et régule négativement l’activité des cellules B. Dans plusieurs études cliniques de stade précoce, 198 sujets ont été traités par l’obéxélimab. Dans le cadre de ces études cliniques, la molécule a démontré une inhibition efficace de la fonction des cellules B sans épuiser les cellules et a généré un effet de traitement encourageant chez les patients atteints de multiples maladies auto-immunes. Zenas a acquis des droits mondiaux exclusifs sur l’obéxélimab auprès de Xencor Inc.

À propos de la ML-IgG4

La ML-IgG4 est une maladie fibroinflammatoire chronique et grave qui affecte généralement plusieurs organes (par ex., pancréas, foie, rein, conduit biliaire, glandes salivaires et lacrymales). Environ 20 000 personnes sont diagnostiquées comme atteintes de ML-IgG4 aux États-Unis, avec des taux de prévalence similaires dans toutes les zones géographiques. De nombreux patients présentent un certain degré de détérioration irréversible de leurs organes au moment du diagnostic. Bien que presque tous les patients répondent initialement au traitement par glucocorticoïdes (GC), une majorité d’entre eux rechutera et/ou présentera une poussée quelques mois après l’arrêt du traitement, nécessitant un traitement de secours. Le traitement chronique par GC est également associé à une toxicité chez de nombreux patients.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients dans le monde entier. Avec un développement et des opérations cliniques à l’échelle mondiale, Zenas fait progresser un portefeuille mondial approfondi et équilibré de thérapies auto-immunes potentielles premières et meilleures de leur catégorie dans des domaines où les besoins médicaux ne sont pas satisfaits, tout en répondant aux exigences de valeur de l’environnement dynamique mondial des soins de santé. Le portefeuille de la société continue de croître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes atteintes de maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le sitewww.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Contact auprès des investisseurs et des médias :
Joe Farmer, président et directeur de l’exploitation
Zenas BioPharma
IR@zenasbio.com

GlobeNewswire Distribution ID 8728679

Nikkiso Clean Energy & Industrial Gases Group Anuncia o Primeiro Teste FAT On-Site na Sua Instalação Naval em Busan, Coreia

TEMECULA, Califórnia, Jan. 11, 2023 (GLOBE NEWSWIRE) — O Nikkiso Clean Energy & Industrial Gases Group (Grupo), parte da Nikkiso Co., Ltd (Japão), tem o orgulho de anunciar a realização do primeiro teste FAT on-site na sua nova instalação naval em Busan, Coreia. Isto é um exemplo do compromisso e apoio do grupo para com a ampliação do mercado coreano.

Desde julho de 2022 a instalação de 4.000 metros quadrados fabrica skids de bomba de alta pressão. O sucesso do teste FAT para a Hapag Lloyd AG (do maior sistema de fornecimento de gás combustível) demonstra a capacidade da fábrica e da instalação de teste de LN2 (nitrogênio líquido). Esta instalação continua a fornecer o suporte de comissionamento e manutenção que já vinha fornecendo. Os recursos de fabricação e teste de skid das bombas HP viabilizam o fornecimento de soluções navais de sistema completo para seus clientes.

O teste FAT é obrigatório antes da entrega do skid, e testa o desempenho geral (ou seja, vazão máxima da bomba, desempenho do vaporizador, sistema de óleo lubrificante (LO), sistema de purga de nitrogênio, válvulas criogênicas, etc.). O teste deve ser testemunhado pelo armador, sociedade de classes e clientes, para verificar se o produto atende aos seus requisitos de desempenho.

De acordo com Jay Lee, Gerente-Geral na Coreia: “A Nikkiso ACD é o fornecedor preferido de skids de Gás Combustível para a indústria de construção naval coreana há mais de 20 anos! Com a nossa nova instalação de embalagem e teste de skid localizada perto dos estaleiros na Coreia, agora temos ainda maior capacidade e suporte local para atender ao substancial aumento e demanda global de novas embarcações de transporte e carga movidas a GNL.”

“Este é o próximo passo importante para o nosso Grupo e para o mercado Naval movido a GNL, e um maior benefício para os nossos clientes da área Naval. A Nikkiso CE&IG agora fornece e testa sistemas completos para nossos clientes, com sistema da fábrica”, disse Peter Wagner, CEO da Cryogenic Industries e Presidente do Grupo.

Informações de Contato:
Nikkiso Clean Energy and Industrial Gases – Coreia
Matriz e Fábrica: 83, Nosansanupjung-ro, Gangseo-gu, Busan, 46752, Coreia do Sul
Escritório: #1912, 170, Gwanggyojungang-ro, Yeongtong-gu, Suwon, Gyeonggi-do, 16614, Coreia do Sul
info@NikkisoCEIG-Korea.com

SOBRE A CRYOGENIC INDUSTRIES
A Cryogenic Industries, Inc. (agora parte da Nikkiso Co., Ltd.) fabrica e presta serviços para equipamentos de processamento de gás criogênico projetados (bombas, turboexpansores, trocadores de calor, etc.) e plantas de processo para Gases Industriais, Liquefação de Gás Natural (GNL), Liquefação de Hidrogênio (LH2) e Ciclo Rankine Orgânico para Recuperação de Calor de Resíduos. Fundada há mais de 50 anos, a Cryogenic Industries é a empresa controladora da ACD, Nikkiso Cryo, Nikkiso Integrated Cryogenic Solutions, Cosmodyne e Cryoquip, e de um grupo comumente controlado de 20 entidades operacionais.

Para mais informação, visite www.nikkisoCEIG.com e www.nikkiso.com.

CONTATO COM A MÍDIA:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

GlobeNewswire Distribution ID 8728366

Nikkiso Clean Energy & Industrial Gases Group annonce son premier test FAT sur site dans son installation maritime à Busan, en Corée

TEMECULA, Californie, 11 janv. 2023 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (le « Groupe »), qui fait partie du groupe de sociétés Nikkiso Co., Ltd (Japon), est fier d’annoncer son premier test FAT (Factory Acceptance Test, test de validation en usine) sur site dans sa nouvelle installation maritime à Busan, en Corée. Cette avancée témoigne de son engagement et de son soutien envers la croissance du marché coréen.

Depuis juillet 2022, il fabrique des patins de pompe haute pression dans l’installation de 4 000 mètres carrés. Avec la réussite de ce test FAT pour Hapag Lloyd AG (pour le plus grand système d’alimentation en gaz combustible), il démontre les capacités de son usine et de son installation d’essai axée sur le LN2 (azote liquide). Cette installation continue d’offrir le soutien à la mise en service et à la maintenance fourni précédemment. Grâce aux capacités de fabrication et de test des patins de pompes HP, il offre désormais à ses clients des systèmes maritimes complets.

Le test FAT est obligatoire avant la livraison des patins. Il s’agit de tester les performances globales (c’est-à-dire le débit maximal de la pompe, les performances du vaporisateur, le système de lubrification, le système de purge d’azote, les vannes cryogéniques, etc.). Il doit être réalisé en présence de l’armateur, de la société de classification et des clients, afin de vérifier que le produit répond aux exigences de performance.

Selon Jay Lee, directeur général pour la Corée, « Nikkiso ACD est le fournisseur de patins pour gaz combustibles privilégié par l’industrie coréenne de la construction navale depuis plus de 20 ans ! Grâce à notre nouveau site de conditionnement et d’essai des patins localisé à proximité des chantiers navals en Corée, nous disposons désormais d’une capacité encore plus grande pour fournir une assistance locale et répondre à la demande mondiale qui est considérable. ».

« C’est une nouvelle étape importante pour notre Groupe et pour le marché du transport maritime alimenté au GNL, ainsi qu’un avantage en plus pour nos clients dans le domaine maritime. Nikkiso CE&IG sera désormais capable de fournir et tester des systèmes complets et de soutenir ses clients avec un système clé en main », a déclaré Peter Wagner, PDG de Cryogenic Industries et président du Groupe.

Coordonnées :
Nikkiso Clean Energy and Industrial Gases – Corée
Siège social et usine : 83, Nosansanupjung-ro, Gangseo-gu, Busan, 46752, Corée
Succursale : #1912, 170, Gwanggyojungang-ro, Yeongtong-gu, Suwon, Gyeonggi-do, 16614, Corée
info@NikkisoCEIG-Korea.com

À PROPOS DE CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (aujourd’hui membre de Nikkiso Co., Ltd.) et ses entreprises membres fabriquent et entretiennent des équipements de traitement du gaz cryogénique (pompes, turbodétendeurs, échangeurs thermiques, etc.), et des usines de traitement pour les gaz industriels, la liquéfaction du gaz naturel (GNL), la liquéfaction de l’hydrogène (LH2) et le cycle organique de Rankine pour la récupération de la chaleur perdue. Fondée il y a plus de 50 ans, Cryogenic Industries est la société-mère d’ACD, de Nikkiso Cryo, de Nikkiso Integrated Cryogenic Solutions, de Cosmodyne et de Cryoquip, et d’un groupe administré en commun comptant vingt entités opérationnelles.

Pour tout complément d’information, veuillez consulter les sites www.nikkisoCEIG.com et www.nikkiso.com.

Contact auprès des médias :
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

GlobeNewswire Distribution ID 8728366

FURA Gems nomme Mazars SA et amorce le processus d’enregistrement auprès du Responsible Jewellery Council (RJC)

FURA Gems

Ruby, Emerald and Sapphire from FURA Gems

DUBAÏ, Émirats arabes unis, 11 janv. 2023 (GLOBE NEWSWIRE) — FURA Gems a annoncé aujourd’hui avoir amorcé le processus de certification avec le Responsible Jewellery Council (RJC), démontrant ainsi son engagement en faveur de pratiques commerciales responsables. Le projet sera pris en charge par Mazars Suisse, qui assistera FURA Gems et tous ses sites d’exploitation minière en Colombie pour les émeraudes, au Mozambique pour les rubis et en Australie pour les saphirs dans le processus de préparation du RJC. FURA a déjà enregistré son site australien auprès du RJC et prévoit maintenant d’étendre la certification au groupe et à l’ensemble de ses sites d’exploitation. Avec le soutien de Mazars, FURA visera à achever le processus de certification au plus tard le 31 décembre 2023 pour tous ses sites d’exploitation.

La certification RJC s’inscrit dans le cadre de l’ambitieuse stratégie ESG déployée par FURA depuis sa création en 2017. Au début de l’année dernière, FURA a annoncé son partenariat avec Gübelin pour assurer la traçabilité de toutes ses pierres grâce à la Provenance Proof Blockchain. La certification RJC marque une étape supplémentaire importante vers la réalisation des objectifs ambitieux de FURA en matière de critères ESG.

« Il s’agit d’une prise de position forte de notre part, car nous lançons la certification de toutes nos mines produisant des émeraudes, des rubis et des saphirs », déclare Dev Shetty, fondateur et PDG de FURA Gems. Le processus de certification nous permettra de formaliser notre engagement depuis notre fondation : fournir au marché de la joaillerie des pierres précieuses de couleur en assurant la traçabilité et la provenance de sources durables. Pour y parvenir, nous avons identifié Mazars comme le partenaire idéal pour mener à bien le processus au siège social comme sur l’ensemble de nos sites de production. Mazars offre la combinaison idéale d’expertise régionale et de perspective mondiale, ce qui nous permet de mener le projet avec le plus haut degré de compétences et de professionnalisme. »

Franck Paucod, associé chez Mazars, ajoute : « Nous sommes ravis d’accompagner FURA Gems dans le processus exigeant de la certification COP du RJC. La réalisation du projet sur les trois (3) mines en même temps témoigne de l’engagement de FURA en faveur de l’exploitation minière responsable. Nous sommes convaincus que notre expertise dans le secteur des pierres précieuses et de la joaillerie nous permettra de soutenir FURA dans son engagement à développer un cadre solide pour l’obtention de la certification RJC. »

À PROPOS DE FURA GEMS

Créée en 2017, FURA Gems Inc. est une société spécialisée dans l’extraction et la commercialisation de pierres précieuses de couleur. Basée à Dubaï, aux Émirats arabes unis, FURA compte plus de 1 200 employés sur tous les continents. Il s’agit de la première entreprise pionnière, créative et éthique à couvrir l’ensemble de la gamme des pierres précieuses de couleur. Elle exploite trois filiales minières en Colombie, au Mozambique et en Australie qui extraient des émeraudes, des rubis et des saphirs. FURA a également lancé son programme de prospection à Madagascar en vue de l’extraction de saphirs. Il s’agit de la société d’extraction de pierres précieuses de couleur qui connaît la plus forte croissance tout en assurant la stabilité et la traçabilité des pierres précieuses de couleur extraites de manière éthique, de l’état brut à la commercialisation.

À PROPOS DE MAZARS

Mazars est un partnership intégré à l’échelle internationale, spécialisé dans l’audit, la comptabilité, le conseil, la fiscalité et les services juridiques. Présent dans plus de 90 pays et territoires à travers le monde, Mazars s’appuie sur l’expertise de plus de 44 000 professionnels pour accompagner ses clients de toutes tailles à chaque étape de leur développement.

Mazars Suisse est spécialisée dans le secteur de l’horlogerie et de la joaillerie. Mazars peut soit accompagner les clients tout au long de la préparation et de l’enregistrement de la certification COP du Code de pratique du RJC, ce qui est le cas pour FURA Gems, soit effectuer des audits pour la certification d’entreprises conformément à la COP du RJC.

Une photo accompagnant ce communiqué de presse est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/80695a84-8e96-48d7-a21d-6548f0e035e7

POUR DE PLUS AMPLES INFORMATIONS

Gianluca Maina, Directeur marketing, FURA Gems, gianluca.maina@furagems.com

Franck Paucod, Associé, Mazars SA, franck.paucod@mazars.ch

GlobeNewswire Distribution ID 1000776856

FURA Gems nomeia Mazars SA e inicia processo de registo junto do Conselho de Joalheria Responsável (RJC)

FURA Gems

Ruby, Emerald and Sapphire from FURA Gems

DUBAI, Emirados Árabes Unidos, Jan. 11, 2023 (GLOBE NEWSWIRE) — A FURA Gems anunciou hoje ter iniciado o processo de certificação junto do RJC, demonstrando o seu compromisso com práticas empresariais responsáveis. O projeto será liderado pela Mazars Suíça, que acompanhará a FURA Gems e todos os respetivos locais de mineração em funcionamento, designadamente na Colômbia para as esmeraldas, Moçambique para os rubis e a Austrália para as safiras, através do processo preparatório do RJC. A FURA já tinha registado a sua unidade australiana junto do RJC, e procurará agora expandir a certificação ao grupo e a todos os respetivos locais de mineração. Com o apoio da Mazars, a FURA terá como meta concluir o processo de certificação até 31 de dezembro de 2023, para todos os respetivos locais de mineração.

A certificação do RJC faz parte da ambiciosa estratégia ESG implementada pela FURA desde a sua fundação, em 2017. No início do ano passado, a FURA anunciou a parceria com a Gübelin para fornecer rastreabilidade a todas as suas pedras através do protocolo de confiança (blockchain) da Provenance Proof. A Certificação do RJC marca um passo adicional importante rumo à concretização das ambiciosas metas ESG estabelecidas pela FURA.

“Trata-se de uma declaração forte da nossa parte, pois estamos a lançar a certificação para todas as nossas minas que produzem esmeraldas, rubis e safiras”, diz Dev Shetty, fundador e CEO da FURA Gems. “Este processo de certificação permitir-nos-á formalizar o compromisso assumido desde a nossa fundação: fornecer ao setor da joalharia pedras preciosas de cor rastreáveis e de origem sustentável. Para tal, identificámos a Mazars como a parceira ideal para conduzir o processo em todas as nossas unidades de produção e ao nível da sede. A Mazars oferece a combinação ideal de experiência regional e perspetiva global, permitindo-nos conduzir o projeto com um enorme nível de competências e profissionalismo.”

Franck Paucod, sócio da Mazars, explica: “Estamos entusiasmados por acompanhar a FURA Gems ao longo deste processo exigente que é a Certificação do Código de Práticas do RJC. A realização do projeto para as três (3) minas em simultâneo mostra o compromisso da FURA em termos de mineração responsável. Estamos confiantes de que, com a nossa experiência no setor das pedras preciosas e das joias, poderemos apoiar a FURA no seu compromisso de construir uma estrutura sólida para a obtenção da certificação RJC.”

SOBRE A FURA GEMS

A FURA Gems Inc. é uma empresa de mineração e comercialização de pedras preciosas de cor criada em 2017. Com sede no Dubai, Emirados Árabes Unidos, a FURA tem mais de 1200 funcionários em todos os continentes. É o primeiro empreendimento pioneiro, criativo e ético a cobrir todo o espectro de pedras preciosas de cor. A empresa opera em três filiais de mineração na Colômbia, Moçambique e Austrália, que extraem esmeraldas, rubis e safiras. A FURA também iniciou o respetivo programa de exploração em Madagáscar para a extração de safiras. É a empresa de mineração de pedras preciosas de cor que mais cresce para garantir a estabilidade e a rastreabilidade de pedras preciosas de cor eticamente extraídas, desde a extração em bruto até à distribuição retalhista.

SOBRE A MAZARS

A Mazars é uma parceria internacionalmente integrada, especializada em auditoria, contabilidade, consultoria, fiscalidade e serviços jurídicos. Com atividade em mais de 90 países e territórios em todo o mundo, a Mazars conta com a experiência de mais de 44 000 profissionais para ajudar clientes de todas as dimensões, em todas as fases do respetivo desenvolvimento.

A Mazars Suíça é especializada nos setores da relojoaria e joalharia. A Mazars pode acompanhar os seus clientes em toda a fase de preparação e registo da certificação do Código de Práticas do RJC, como é o caso da FURA Gems, ou realizar auditorias para a certificação das empresas em conformidade com o CdP do RJC.

Foto deste comunicado disponível em: https://www.globenewswire.com/NewsRoom/AttachmentNg/80695a84-8e96-48d7-a21d-6548f0e035e7

MAIS INFORMAÇÕES

Gianluca Maina, Diretor de Marketing, FURA Gems, gianluca.maina@furagems.com

Franck Paucod, Sócio, Mazars SA, franck.paucod@mazars.ch

GlobeNewswire Distribution ID 1000776856

Lisa Marie Presley, Singer and Daughter of Elvis, Dies at 54

Lisa Marie Presley, a singer-songwriter, Elvis' only daughter, and a dedicated keeper of her father's legacy, died Thursday after being hospitalized for a medical emergency. She was 54.

Her death in a Los Angeles hospital was confirmed by her mother, Priscilla, a few hours after her daughter was rushed to the hospital after having a medical emergency at home.

"It is with a heavy heart that I must share the devastating news that my beautiful daughter Lisa Marie has left us," Priscilla Presley said in a statement. "She was the most passionate, strong and loving woman I have ever known."

Presley, the only child of Elvis and Priscilla Presley, shared her father's brooding charisma — the hooded eyes, the insolent smile, the low, sultry voice — and followed him professionally, releasing her own rock albums in the 2000s, and appearing on stage with Pat Benatar and Richard Hawley among others.

She even formed direct musical ties with her father, joining her voice to such Elvis recordings as "In the Ghetto" and "Don't Cry Daddy," a mournful ballad that had reminded him of the early death of his mother (and Lisa Marie's grandmother), Gladys Presley.

"It's been all my life," she told The Associated Press in 2012, speaking of her father's influence. "It's not something that I now listen to and it's different. Although I might listen closer. I remain consistent on the fact that I've always been an admirer. He's always influenced me."

Famous from the start

Her birth, nine months exactly after her parents' wedding, was international news and her background was rarely far from her mind. With the release last year of Baz Luhrmann's major musical feature "Elvis," Lisa Marie and Priscilla Presley had been attending red carpets and award shows alongside stars from the film.

She was at the Golden Globes on Tuesday, on hand to celebrate Austin Butler's award for playing her father. Just days before, she was in Memphis at Graceland — the mansion where Elvis lived and died — on January 8 to celebrate her father's birth anniversary.

Presley lived with her mother, an actor known for "Dallas" and the "Naked Gun" movies, in California after her parents split up in 1973. She recalled early memories of her dad during her visits to Graceland, riding golf carts through the neighborhood, and seeing his daily entrances down the stairs.

"He was always fully, fully geared up. You'd never see him in his pajamas coming down the steps, ever," she told The Associated Press in 2012. "You'd never see him in anything but 'ready to be seen' attire."

Elvis Presley died in August 1977, when he was just 42, and she 9 years old. Lisa Marie was staying at Graceland at the time and would recall him kissing her goodnight hours before he would collapse and never recover. When she next saw him, the following day, he was lying face down in the bathroom.

"I just had a feeling," she told Rolling Stone in 2003. "He wasn't doing well. All I know is I had it (a feeling), and it happened. I was obsessed with death at a very early age."

Life in the spotlight

She would later make headlines of her own. Struggles with drugs and some very public marriages. Her four husbands included Michael Jackson and Nicolas Cage.

Jackson and Presley were married in the Dominican Republic in 1994, but the marriage ended two years later and was defined by numerous awkward public appearances, including an unexpected kiss from Jackson during the MTV Video Music Awards and a joint interview with Diane Sawyer when she defended her husband against allegations he had sexually abused a minor.

Her other celebrity marriage was even shorter: Cage filed for divorce after four months of marriage in 2002.

"I had to sort of run into many walls and trees," she told the AP in 2012. "But now I can also look back at it and tell you all the stuff that was going on around me and all the different people around me and all the awww — and it was not a good situation anyway. That wasn't helping. Either way, it was a growing process. It was just in a different way. It was just out in front of everybody all the time. Because it's all documented of course."

Lisa Marie became involved in numerous humanitarian causes, from anti-poverty programs administered through the Elvis Presley Charitable Foundation to relief efforts after Hurricane Katrina. She would receive formal citations from New Orleans and Memphis, Tennessee for her work.

Presley had two children, actor Riley Keough and Benjamin Keough, with her former husband Danny Keough. She also had twin daughters with ex-husband Michael Lockwood.

Benjamin Keough died by suicide in 2020 at the age of 27. Presley was vocal about her grief, writing in an essay last August that she had "been living in the horrific reality of its unrelenting grips since my son's death two years ago."

"I've dealt with death, grief and loss since the age of 9 years old. I've had more than anyone's fair share of it in my lifetime and somehow, I've made it this far," she wrote in an essay shared with People magazine.

"But this one, the death of my beautiful, beautiful son? The sweetest and most incredible being that I have ever had the privilege of knowing, who made me feel so honored every single day to be his mother? Who was so much like his grandfather on so many levels that he actually scared me? Which made me worry about him even more than I naturally would have?" the essay continued. "No. Just no ... no no no no ..."

Graceland

Lisa Marie became the sole heir of the Elvis Presley Trust after her father died. Along with Elvis Presley Enterprises, the trust managed Graceland and other assets until she sold her majority interest in 2005. She retained ownership of Graceland Mansion itself, the 13 acres around it, and items inside the home. Her son is buried there, along with her father and other members of the Presley family.

Lisa Marie Presley is a former Scientologist — her son was born in 1992 under guidelines set by Church of Scientology founder L. Ron Hubbard, according to an AP story at the time — but later broke with Scientology.

Lisa Marie and Priscilla Presley would make regular trips to Graceland during huge fan celebrations on the anniversaries of Elvis' death and birthday. One of the two airplanes at Graceland is named the Lisa Marie.

After her first album "To Whom It May Concern," in 2003, some fans came out to see her perform just out of curiosity given her famous family, she told the AP in 2005.

"First I had to overcome a pre-speculated idea of me," she said of the barriers to becoming a singer-songwriter.

"I had to sort of burst through that and introduce myself, and that was the first hurdle, and then now sing in front of everybody, and then that was the second one, and I'm the offspring of — you know, who I'm the offspring of — I had a few hurdles to get through, no doubt about it," she continued. "But the scales never tipped in the other direction too much."

Source: Voice of America

As COVID Rips Across China, One Family Counts 5 Dead

Guan Yao, who lives in California, never thought that on his last video chat with his grandmother in Beijing he would watch her die.

He had installed a tiny robot camera in his grandmother's home some time ago so they could be in constant contact after he moved to the U.S. in 2016. She took to the device, holding it almost as if it provided the comfort of his touch.

Guan was video chatting with her throughout the last four hours of her life on December 22.

The 85-year-old had tested positive for COVID-19 and had had a fever for days. Two days before dying, she finally got a bed in a hospital.

Guan watched her blood oxygen saturation level suddenly turn from a low of 70 to a question mark. The doctor announced her death after an electrocardiogram.

"Her final death certificate said kidney failure because she had kidney disease before," Guan told VOA Mandarin from his home in the Los Angeles area. "Not COVID."

On the same day, the Chinese Center for Disease Control and Prevention issued an epidemic report stating that "there were no new deaths of COVID."

Before his grandmother died, Guan, 39, an IT professional, had already lost four relatives in his extended family since December 14: his father-in-law, his father, an uncle and another elderly female relative. Among them, only Guan's grandmother and uncle had tested positive for COVID-19. The others died before getting tested.

His father-in-law died of asthma. His father had heart disease and died in his sleep. His uncle's medical images showed the white lungs associated with COVID-19 when he was sent to the hospital, but his death certificate states Parkinson's disease as the cause.

China's "zero-COVID" policy reversed almost overnight after three years on December 7, when the government issued the "New Ten Measures" for epidemic prevention that announced the relaxation of coronavirus-containment controls.

A tsunami-like COVID outbreak followed, its magnitude suggested by countless tragedies reported every day on social media despite China's relentless internet censorship.

"The last day of 2022 ended with a funeral, and 2023 started with another funeral. In just half a month, the old people around here have been infected and died one after another. The sadness is lasting a bit too long," wrote a poster from Jiangsu province.

"I work in a hospital, and I see people die every day. The crematorium works 24 hours every day, but people still have to wait in line," wrote a poster from Guangdong.

Guan said, "The reopening was too sudden, prompting such a large-scale outbreak, and the medical system was completely unprepared for a large number of infection cases."

Until January 7, the official death toll from COVID-19 remained at 30.

"The statistics are definitely underreported by a lot," said Guan, a political activist who is a board member of Dialogue China, a nongovernmental think tank established by Tiananmen student leader Wang Dan. "My aunt said that she was in the emergency room and saw four or five people die and be carried away in such a short period of time."

Tan Hua, who is in Shanghai and is infected with COVID-19, told VOA Mandarin that “we don't have access to the official data now, and we don't pay attention to the data on severe disease and death, because it's completely inconsistent with how we feel around us."

When Guan's father died, the family found a one-stop service from the funeral home and spent about 30,000 yuan or roughly $4,400 to cremate him — twice the usual price. Without paying extra, they had to wait in a long queue.

When Guan's grandmother died, the hospital said the government had a collective arrangement and that all the bodies would be stored in the funeral home, waiting for collective cremation.

An official notice informed the family that the morgues in hospitals and funeral homes were full and that local warehouses had been turned into temporary morgues until the collective cremation scheduled for January 19.

For unknown reasons, Guan said his grandmother's body was not sent to the temporary morgue and was cremated on December 31.

Three years ago, when the pandemic broke out in Wuhan, Guan bought masks for his family in Beijing and told them not to believe the government. He thought they were spreading lies to cover up the pandemic. He never imagined that after three years of lockdown, China would witness death on such a scale.

"The three years [of lockdown] were meaningless," Guan said. "It's really unacceptable that so many loved ones have passed away. Whenever I think about it, I get really, really angry and sometimes I bang on the table at breakfast."

When other overseas Chinese media approached Guan, hoping to interview him about the deaths in his family, he declined.

"I worried that they [the government] were going to do something under the rug," he said. "My grandmother was such an important relative, and if she couldn't be cremated because of my [media] appearance, my family would hate me for the rest of my life."

Now that all five of his relatives have been cremated, Guan said that he doesn't mind telling his story.

"Five relatives left in eight days. It's too unusual. Someone has to tell the story," he said.

The Lunar New Year arrives on January 22 this year. Guan’s father always spent New Year's Eve with his mother, Guan's grandmother. Being so far away across the Pacific Ocean, Guan would make video calls to his grandmother on the holiday, sharing New Year’s blessings, chatting about family affairs and making jokes.

This year, he keeps thinking of his grandmother who died not knowing that her only son had died three days before her.

"There is no one left home," Guan said. "To be honest, there is nothing to celebrate this year."

Source: Voice of America